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Abstract
Background:  The combination therapy of interferon (IFN)-alpha and 5-fluorouracil (5-FU) improved the
prognosis of the patients with hepatocellular carcinoma (HCC). To determine the molecular mechanisms of the
anti-tumor and anti-angiogenic effects, we examined the direct anti-proliferative effects on human umbilical vein
endothelial cells (HUVEC) and indirect effects by regulating secretion of angiogenic factors from HCC cells.
Methods: The direct effects on HUVEC were examined by TUNEL, Annexin-V assays and cell cycles analysis.
For analysis of the indirect effects, the apoptosis induced by the conditioned medium from HCC cell treated by
IFN-alpha/5-FU and expression of angiogenic factors was examined.
Results:  IFN-alpha and 5-FU alone had anti-proliferative properties on HUVEC and their combination
significantly inhibited the growth (compared with control, 5-FU or IFN alone). TUNEL and Annexin-V assays
showed no apoptosis. Cell cycle analysis revealed that IFN-alpha and 5-FU delayed cell cycle progression in
HUVEC with S-phase accumulation. The conditioned medium from HuH-7 cells after treatment with IFN/5-FU
significantly inhibited HUVEC growth and induced apoptosis, and contained high levels of angiopoietin (Ang)-1 and
low levels of vascular endothelial growth factor (VEGF) and Ang-2. Knockdown of Ang-1 in HuH-7 cells abrogated
the anti-proliferative effects on HUVEC while knockdown of Ang-2 partially rescue the cells.
Conclusion: These results suggested that IFN-alpha and 5-FU had direct growth inhibitory effects on endothelial
cells, as well as anti-angiogenic effects through regulation of angiogenic factors released from HCC cells.
Modulation of VEGF and Angs secretion by IFN-alpha and 5-FU may contribute to their anti-angiogenic and anti-
tumor effects on HCC.
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Background
Hepatocellular carcinoma (HCC) is one of the most com-
mon malignancies worldwide, especially in Eastern Asia.
Advancements in diagnostic biotechnology and new ther-
apeutic modalities have improved the prognosis of
patients with small HCC. However, the entire prognosis
of patients with HCC is still poor, particularly in patients
with tumor thrombi in the major trunk of the portal vein,
because HCC can invade the portal vein in the early
period and cause intrahepatic metastases. Although chem-
otherapy commonly plays a central role in the treatment
of advanced stage HCC, no standard treatment regimen
has been established yet [1], because of resistance of such
tumors to anti-cancer drugs [2]. Recently, we and others
reported that the combination of interferon (IFN) and
chemotherapeutic agents for advanced HCC resulted in
excellent clinical outcome [3-6]. The clinical response rate
(CR and PR ration) of patients with unresectable
advanced HCC and portal vein tumor thrombosis to the
combination therapy of IFN-α and hepatic arterial infu-
sion of 5-fluorouracil (5-FU) is about 50% [6]. Further-
more, combining this therapy with surgery can reduce
recurrence [3,4].
The exact mechanism of action of this combination ther-
apy is not clear at present. The IFNs are a family of natural
glycoproteins and regulatory cytokines with pleiotropic
cellular functions, such as anti-viral, anti-proliferative and
immunomodulatory activities [7-9]. IFN-α enhances the
anti-tumor effects of 5-FU by regulating thymidine phos-
phorylase and accumulation of fluorodeoxyuridine
monophosphate (FdUMP) caused by inhibition of thymi-
dylate [10]. We reported previously that the expression of
IFN-α/β receptor correlates with the growth-inhibitory
activity and that IFN-α and 5-FU synergistically inhibit
cell proliferation, induced cell cycle arrest [11,12], and
induce apoptosis by regulating the expression of apopto-
sis-related molecules [13]. IFN-α also has immunomodu-
latory properties and the tumor necrosis factor-related
apoptosis inducing ligand (TRAIL) or Fas/Fas-L pathway
partially contributes to the anti-tumor effects of IFN-α/5-
FU combination therapy [14,15]. On the other hand, IFNs
also has significant antitumor activity through the inhibi-
tion of angiogenesis in experimentally-induced tumors in
animals [16]. Specifically, IFNs regulates the transcription
and production of pro-angiogenic molecules, such as vas-
cular endothelial growth factor (VEGF) [17,18], basic
fibroblast growth factor (b-FGF) [19], matrix metallopro-
teinase (MMP)-2 and MMP-9 [20,21], and interleukin
(IL)-8 [22]. Marschall et al. [17] recently reported that the
therapeutic effects of IFN-α on neuroendocrine tumor
cells were based on Sp1- and/or Sp3-mediated inhibition
of VEGF transcription both in vivo and in vitro. We also
reported recently that IFN-α and 5-FU combination ther-
apy synergistically inhibited tumor angiogenesis in vivo
and their effects correlated with regulation of VEGF and
angiopoietins (Angs) [16].
The present study is an extension to the above studies and
was designed to determine the direct effects of IFN-α and
5-FU on endothelial cells, using cultured human umbili-
cal vein endothelial cells (HUVEC). Moreover, we also
determined the indirect effects of IFN-α and 5-FU on
endothelial cells mediated through various angiogenic
factors secreted by HCC cell lines and examined their
effects on endothelial cells, with a special focus on VEGF
and Angs.
Methods
Cell lines and reagents
HCC cell line HuH7 was maintained as an adherent mon-
olayer in Dulbecco's modified Eagle's medium (DMEM)
supplemented with 10% fetal bovine serum (FBS) and 1%
penicillin-streptomycin mixture. HUVEC were grown on
MCDB131 culture medium (Chlorella, Inc., Tokyo,
Japan) supplemented with 5% fetal bovine serum, antibi-
otics and 10 ng/mL basic fibroblast growth factor (bFGF).
Cell cultures were grown on plastic plates and incubated
at 37°C in a mixture of 5% CO2 and 95% air. Purified
human IFN-α was obtained from Otsuka Pharmaceutical
Co. (Tokushima, Japan) and purified 5-FU was obtained
from Kyowa Hokko Co. (Tokyo).
Growth inhibitory assay
HUVEC (1 × 104 cells per well) were added in triplicate to
a 96-well microplate, and after overnight incubation, the
medium was replaced with 0.1 ml of fresh medium con-
taining various concentrations of 5-FU and/or IFN-α.
HUVEC cells suspended in complete medium were used
as control for cell viability. After 72-hour treatment, the
number of viable cells was assessed by the 3-(4-, 5-
dimethylthiazol-2-yl)-2, 5-dyphenyl tetrazolium bromide
(MTT) (Sigma Co, St. Louis, MO) assay as reported previ-
ously [12]. Briefly, 10 μl (50 μg) of MTT were added to
each well. The plate was incubated for 4 h at 37°C, fol-
lowed by removal of the medium and addition of 0.1 ml
of 2-propanol to each well to dissolve the resultant forma-
zan crystals. Plate absorbance was measured in a micro-
plate reader at a wavelength of 570 nm. These assays were
repeated three times, and similar results were obtained. In
other parts of the present study, experiments were
repeated at least twice, and no discrepant results were
obtained.
Growth curves for each treatment were constructed as fol-
low. Cells were uniformly seeded in triplicates into 6-well
dishes. Twenty-four hours later (day 0), the culture
medium was replaced with 3 ml of fresh medium with orBMC Cancer 2009, 9:361 http://www.biomedcentral.com/1471-2407/9/361
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without 5-FU (0.5 μg/ml) and IFN-α (500 units/ml). The
medium was changed every 48 h, and on days 1, 3, 5 and
7, cell numbers were counted using a hemocytometer by
trypan blue dye exclusion.
Cell cycle analysis
Flow cytometric analysis was performed as described pre-
viously [12]. Briefly, cells were washed twice with PBS and
fixed overnight in 70% ethanol before being washed and
resuspended in 1 ml of PBS. Propidium iodide (Sigma-
Aldrich, St. Louis, MO) and RNase (Nippon Gene, Tokyo)
were added for 30 min at 37°C. Samples were filtered
through 44 μm nylon mesh and data were acquired with
a FACSort (Becton Dickinson Immunocytometry Systems,
San Jose, CA). Analysis of the cell cycle was carried out
using ModFit software (Becton Dickinson).
BrdU labeling index
Cells were incubated with 20 μmol/L BrdUrd (Sigma-
Aldrich) at 37°C for 30 minutes and fixed in 70% cold
ethanol for 30 minutes. After quenching endogenous per-
oxidase activity, the slides were incubated in 4 N HCl at
37°C for 5 minutes and neutralized with buffered boric
acid (pH 9.0) for 5 minutes. After blocking with 10% rab-
bit serum, anti-BrdUrd antibody (DAKO, Glostrup, Den-
mark) was applied to the slides at 1:20 dilution at room
temperature for 2 hours followed by the avidin-biotin
complex method. For quantification, five microscopic
fields were randomly selected at high power magnifica-
tion (× 200) and the percentage of BrdU-positive cells was
calculated as described previously [23].
Detection of apoptosis
To detect apoptosis, we used the terminal deoxynucleoti-
dyl transferase-mediated dUTP nick end-labeling
(TUNEL) method using the Apop Tag in situ apoptosis
detection Kit (Chemicon International, Inc., Temecula,
CA) as described previously [13]. This method can detect
fragmented DNA ends of apoptotic cells. Briefly, the par-
affin-embedded sections were deparaffinized in xylene
and rehydrated in a graded series of ethanol baths. The
sections were treated with 20 μg/ml of proteinase K in dis-
tilled water for 10 min at room temperature. The adherent
cultured HUVEC cells were fixed in 1% paraformaldehyde
for 10 minuets. To block endogenous peroxidase, the
slides incubated in methanol containing 0.3% hydrogen
peroxide for 20 min. The remaining procedures were per-
formed according to the instructions provided by the
manufacturer. For quantification of apoptosis, five micro-
scopic fields were randomly selected at high power mag-
nification (× 200) and the average counts of TUNEL-
positive cells were calculated.
The binding of annexin V-FITC was also used as a sensitive
method for measuring apoptosis, according to the
method described previously [14]. Briefly, after treatment
with IFN-α and/or 5-FU, the cultured cells (1 × 106) were
incubated with binding buffer (10 mM HEPES, 140 mM
NaCl and 2.5 mM CaCl2, pH 7.4) containing saturating
concentrations of annexin V-FITC (BioVision Research
Products, Mountain View, CA) and propidium iodide (PI)
for 15 min at room temperature. After incubation, the
cells were pelleted and analyzed on a FACScan (BD), and
data were processed using Cell Quest™ software (BD).
In vitro angiogenesis assay
In vitro formation of tubular structures in HUVEC was
examined using in vitro Angiogenesis Assay kit (Chemi-
con). HUVEC cells were seeded on Matrigel-coated well
and maintained on complete medium. After attachment
of the cells on Matrigel, the medium was changed with
fresh medium, either with or without the recombinant
VEGF protein (25 ng/mL), and incubated for 12 hours.
Cells were then observed under an inverted microscope
and the number of capillary structures was counted as
reported previously [23] and according to recommended
procedure by the respective manufacturer, we counted the
capillary tube branch points in ten random view-fields per
well and calculated the average of branch points.
Effect of conditioned medium from cancer supernatants 
on HUVEC proliferation
To evaluate anti-angiogenic effects mediated by ang-
iogenic factors released from cancer cells, we used super-
natants from HuH-7 in subsequent experiments. To
obtain supernatants from cultured cancer cells as condi-
tioned medium (CM), HuH-7 cells were seeded on 150-
mm dishes containing medium with 10% FBS. After 24
hours, the medium was replaced with serum-free UltraC-
ulture medium (Calbiochem, La Jolla, CA), containing
IFN-α (500 IU/ml) and/or 5-FU (0.5 μg/ml). The medium
was collected after 48 hours. Then, HUVEC were cultured
in CM in each treatment and their proliferation was eval-
uated by MTT assay and the frequency of apoptosis by
TUNEL assay.
ELISA assays for VEGF, Ang-1 and Ang-2 in cell culture 
supernatants
HuH7 cells (3 × 104) were seeded into 12-well plates and
incubated overnight. After overnight incubation, the cul-
ture medium was removed and replaced with 2 ml of
DMEM with or without 5-FU (0.5 μg/ml) and IFN-α (500
IU/ml). The conditioned medium in each group was col-
lected after 48 h. VEGF, Ang-1 and Ang-2 levels were ana-
lyzed using the human VEGF enzyme-linked
immunosorbent assay (ELISA) kit (Biosource Interna-
tional, Camarillo, CA), the Quantikine human Ang-1
ELISA kit (R&D Systems, Minneapolis, MN) and the
Quantikine human Ang-2 ELISA kit (R&D Systems),BMC Cancer 2009, 9:361 http://www.biomedcentral.com/1471-2407/9/361
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respectively. These ELISA assays were performed as recom-
mended by the respective manufacturer.
Ang-1 or Ang-2 specific siRNA knockdown
SiTrio Ang-1, Ang-2 and negative control small interfering
RNA (siRNA) were purchased from B-Bridge Interna-
tional, Inc. (Sunnyvale, CA). Each siRNA consisted of
three different target sequences; which were as follows:
negative control 5 TCCGCGCGATAGTACGTA- 3, 5-
TTACGCGTAGCGTAATACG-3, and 5 ATTCGCGCGTAT-
AGCGGT-3 and siRNA Ang-1 human, 5-CGCUG-
GAGCCCGUGAAAAATT- 3, 5-CCAGAGUGAUCA AGU
GUGATT- 3, and 5-UCCAAUAGGUGUAGGAAAUTT-3.
Cells were transfected with 100 nmol/L siRNA using Lipo-
fectAMINE 2000 (Invitrogen, Carlsbad, CA) in Opti-MEM
I Reduced Serum Medium (Invitrogen). After 6 hours,
medium was replaced by standard medium. At 24 hours
after transfection, the medium was replaced with serum-
free medium with or without IFN-α (500 IU/ml) and/or
5-FU (0.5 μg/ml). These media were collected after 48
hours, and HUVEC were cultured in each medium fol-
lowed by evaluation of proliferation by MTT assay and fre-
quency of apoptosis by TUNEL assay.
Statistical analysis
Data are expressed as mean ± SD. Statistical analysis was
performed using the StatView J-4.5 program (Abacus Con-
cepts, Inc., Berkeley, CA). The unpaired Student's t-test
was used to examine differences in cell proliferation,
apoptosis, BrdUrd labeling index and the expression of
VEGF, Ang-1, Ang-2 proteins between each group. A p
level less than 0.05 was considered statistically significant.
Results
Anti-proliferative effects of IFN/5-FU on HUVEC
To evaluate the effect of IFN-α and 5-FU on proliferation
of HUVEC, we performed growth inhibitory assays by
MTT assay. Cells were exposed to 5-FU and/or IFN-α for
MTT growth inhibitory assay Figure 1
MTT growth inhibitory assay. 5-FU alone inhibited HUVEC cells growth (A). IFN-α alone slightly inhibited HUVEC cell 
growth, even when used at a high concentration (10,000 units/ml) (B). Significant synergistic effects for IFN-α and 5-FU were 
observed at 0.05 μg/ml of 5-FU and 500 or 5,000 units/ml of IFN-α (p < 0.05), but not at 0.5 or 5 μg/ml of 5-FU plus 500 units/
ml of IFN-α (C). A significant difference was observed in cell numbers on day 7 between the IFN/5-FU combination group and 
the other groups (D).BMC Cancer 2009, 9:361 http://www.biomedcentral.com/1471-2407/9/361
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72 hours at various concentrations. 5-FU alone inhibited
HUVEC cells growth (Figure 1A); the IC50 of 5-FU was
3.06 ± 0.48 μg/ml. IFN-α alone slightly inhibited HUVEC
growth, but even at high concentrations (10,000 units/
ml), IFN-α moderately reduced cell growth to 62.0 ± 4.5%
(Figure 1B). When IFN-α and 5-FU were used simultane-
ously at various concentrations, significant effects were
observed at 0.05 μg/ml of 5-FU plus 500 or 5,000 units/
ml of IFN-α (p < 0.05). However, these effects were not
observed with 0.5 or 5 μg/ml of 5-FU plus 500 units/ml of
IFN-α (Figure 1C). Growth curves were constructed up to
7 days (Figure 1D). The doubling times were 29.7, 34.2,
45.5 and 78.9 h for cultures of control, 5-FU alone, IFN-α
alone and 5-FU plus IFN-α, respectively. A significant dif-
ference was observed in cell numbers at day 7 between the
IFN/5-FU combination group and other groups.
Cell cycle analysis
Next, we performed flow cytometric analyses to examine
changes in cell cycle progression when HUVEC cells were
treated with or without IFN-α (500 units/ml) and/or 5-FU
(0.5  μg/ml). To synchronize the cell cycle in G0-G1,
HUVEC cells were pre-treated by 2 μM aphidicolin
(Sigma-Aldrich) for 16 h before the addition of IFN-α/5-
FU. Cells were then collected 12, 24, 48 and 72 h later.
Flow cytometric data confirmed that after pre-treatment
with aphidicolin, the majority of cells (86.3%) were in
G0-G1. At 24 h, IFN-α alone and IFN/5-FU increased the
Flow cytometric analysis of cell cycle progression in HUVEC cells treated with or without IFN-α (500 units/ml) and/or 5-FU  (0.5 μg/ml) Figure 2
Flow cytometric analysis of cell cycle progression in HUVEC cells treated with or without IFN-α (500 units/ml) 
and/or 5-FU (0.5 μg/ml). To synchronize the cell cycle in G0-G1, HUVEC cells were first pre-treated with 2 μM aphidicolin 
for 16 h. Cells were collected 12, 24, 48 and 72 h later. After pre-treatment by aphidicolin, the majority of cells (86.3%) were 
in G0-G1. At 24 h, IFN-α alone and IFN/5-FU increased the number of cells with S-phase DNA content. At 48 h and 72 h, IFN/
5-FU still resulted in S-phase accumulation.BMC Cancer 2009, 9:361 http://www.biomedcentral.com/1471-2407/9/361
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number of cells with S-phase DNA content. At 48 and 72
h, IFN/5-FU still showed S-phase accumulation (Figure
2). These results suggest that IFN-α can regulate the cell
cycle and that IFN/5-FU delayed the cell cycle of HUVEC
in the S-phase.
BrdUrd labeling index
We also assessed cell growth and DNA synthesis using
BrdUrd. 5-FU alone and IFN/5-FU caused a significant
decrease in BrdUrd labeling index than control and IFN-α
alone (p < 0.01). There was no difference in BrdUrd labe-
ling index between 5-FU alone and the combination of
IFN/5-FU (Figure 3A, B). These results suggest that 5-FU
inhibits DNA synthesis in HUVEC.
IFN-α directly inhibits tube formation in vitro
In vitro angiogenesis assay showed that HUVEC formed
vessel-like structures (tubes) when plated on Matrigel-
coated wells (Figure 3A). 5-FU treatment did not inhibit
tube formation or network formation. In contrast, thin or
only weakly-stained tube-like structures were noted in the
presence of IFN-α. The combination of IFN/5-FU also
BrdUrd labeling index and tube formation in vitro Figure 3
BrdUrd labeling index and tube formation in vitro. (A) In vitro angiogenesis assay showed that HUVEC formed vessel-
like structures (tubes) when plated on Matrigel-coated wells. 5-FU treatment did not inhibit tube and network formation. In 
contrast, IFN-α caused thinner or only weakly-stained tube-like structures. IFN/5-FU also inhibited tube formation compared 
to the control and caused only weak staining of the tube-like structures, similar to IFN-α alone. (B) 5-FU alone and IFN/5-FU 
caused significant decreases in BrdUrd labeling index compared with the control and IFN-α alone (p < 0.01). There was no dif-
ference in the index between 5-FU alone and IFN/5-FU combination (A, B). There was a significant difference in the number of 
capillary connections, defined as cross-points consisting of three tubes, among the control, 5-FU alone and IFN-α, IFN/5-FU (p 
< 0.01).BMC Cancer 2009, 9:361 http://www.biomedcentral.com/1471-2407/9/361
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inhibited tube formation compared to the control and
their presence was associated with only weakly-stained
tube-like structures, similar to IFN-α alone. There was a
significant difference in the number of capillary connec-
tions, defined as cross-points consisting of three tubes
among the control, 5-FU alone and IFN-α, IFN/5-FU (p <
0.01; Figure 3B). These results suggest that IFN-α sup-
presses HUVEC tube formation and that 5-FU does not
cause further inhibition of this action.
IFN/5-FU do not directly induce HUVEC apoptosis
To examine whether the anti-proliferative effects of IFN/5-
FU on HUVEC represent induction of apoptosis, we used
TUNEL assay and Annexin V assay. TUNEL assay showed
that TUNEL-positive cells were hardly found in each treat-
ment at all (Figure 4A). To confirm these results, we per-
formed the annexin-V assay to detect pre-apoptotic cells.
Similarly, IFN/5-FU did not induce HUVEC apoptosis
(Figure 4B).
CM from HuH-7 treated by IFN/5-FU inhibits HUVEC 
growth
Next, we investigated the anti-angiogenic effects of ang-
iogenic factors secreted by cancer cells using supernatants
from HuH-7 as the conditioned medium (CM). Com-
pared to serum-free medium, CM from control cultures of
Effect of 5-FU alone and IFN-α, IFN/5-FU on apoptosis of HUVEC Figure 4
Effect of 5-FU alone and IFN-α, IFN/5-FU on apoptosis of HUVEC. (A) TUNEL assay showed limited number of 
TUNEL-positive cells in each treatment. (B) IFN/5-FU did not induce apoptosis of HUVEC in annexin-V assay. The percentage 
of Annexin-V positive cells is shown in figures. (C) Serum-free CM from control culture of HuH-7 significantly promoted 
HUVEC growth. Supernatants from HuH-7 treated by IFN-α (500 units/ml) and 5-FU (0.5 μg/ml) (CM-IFN/5-FU) significantly 
inhibited the growth of HUVEC. (D) Growth inhibition of CM-IFN/5-FU was due to induction of apoptosis. The number of 
TUNEL-positive cells in CM-IFN/5-FU was significantly higher than in other conditioned media (Figure 4D).BMC Cancer 2009, 9:361 http://www.biomedcentral.com/1471-2407/9/361
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HuH-7 cells significantly promoted HUVEC growth. The
supernatants of IFN-α (500 units/ml) and 5-FU (0.5 μg/
ml) treated HuH-7 cells (CM-IFN/5-FU) significantly
inhibited the growth of HUVEC (Figure 4C). There were
significant differences between CM-IFN/5-FU and each of
CM-control, CM-IFN and CM-5-FU. In the next step, we
confirmed by TUNEL assay, that the growth inhibition of
CM-IFN/5-FU was related to induction of apoptosis (Fig-
ure 4D). The number of TUNEL-positive cells in CM-IFN/
5-FU was significantly higher than that in the other condi-
tioned media.
IFN-α/5-FU inhibit VEGF and Ang-2 and enhance Ang-1 
production in vitro
We also examined the angiogenic factors (VEGF, Ang-1
and Ang-2) secreted in the supernatant of HCC cells using
the respective ELISA kits. Treatment of cells with the com-
bination of IFN-α and 5-FU resulted in a significant reduc-
tion in the concentration of secreted VEGF and Ang-2 and
increased secretion of Ang-1 in culture supernatant com-
pared with the control (Figure 5).
Ang-1 or Ang-2 knockdown abrogates anti-proliferative 
effects of conditioned medium
To determine that angiopoietins from IFN/5-FU-treated
tumor cells mediated the observed proliferative and apop-
totic effects, we evaluated whether endogenous expression
of Ang-1 and Ang-2 are required anti-proliferative effects
of the supernatants of IFN/5-FU treated HuH-7 cells using
Ang-1 and Ang-2 siRNAs. Transfection of Ang-1 or Ang-2
siRNA into HuH-7 cells clearly down-regulated their
expression to less than 30% of the control (Figure 6A).
Knockdown of Ang-1 completely abrogated the anti-pro-
liferative effects of the CM from IFN/5-FU-treated
HUVEC, while Ang-2 knockdown partially rescued
HUVEC growth (Figure 6B). These results suggest that the
combination of IFN and 5-FU regulates the expression of
angiopoietins and Ang-1 and Ang-2 mediate, at least in
part, the anti-angiogenic effects of this combination ther-
apy for HCC.
Discussion
In HCC, as part of the remodeling of the hepatic structures
from normal liver to cirrhotic liver, inflammation and tis-
sue reconstruction stimulates angiogenesis. Furthermore,
HCC is known as one of the most hypervascular tumors
and angiogenesis is necessary for its development. Solid
tumors cannot grow beyond 2-3 mm without new blood
vessels due to lack of oxygen and nutrients [24]. Once
angiogenesis starts, the tumor grows rapidly, invades
other organs and metastasizes to remote sites [25]. This is
a multi-step process regulated by a balance between
inducers and inhibitors of endothelial cells proliferation
and migration. These pro- and anti- angiogenic molecules
are produced by tumors and host components cells [26].
To date, many factors known to promote or inhibit angio-
genesis have been identified, including growth factors,
cytokines and proteases [27]. Previous studies showed
that IFN-α has anti-angiogenic properties in various
tumors such as Kaposi's sarcomas [28], infantile hemangi-
Concentrations of angiogenic factors (VEGF, Ang-1 and Ang-2) in the supernatants of HCC cells treated without (control) or  with IFN-α, 5-FU or their combination, measured by ELISA assay kits Figure 5
Concentrations of angiogenic factors (VEGF, Ang-1 and Ang-2) in the supernatants of HCC cells treated with-
out (control) or with IFN-α, 5-FU or their combination, measured by ELISA assay kits.BMC Cancer 2009, 9:361 http://www.biomedcentral.com/1471-2407/9/361
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omas [29] and some vascular-rich malignancies,
melanoma, renal cell carcinoma and neuroendocrine
tumors [30]. Therefore, we focused in the present study on
the anti-angiogenic effects of the combination of IFN-α
and 5-FU to determine the mechanism of action.
Firstly, we examined whether IFN-α or 5-FU has anti-pro-
liferative properties on endothelial cells using HUVEC.
The results of MTT assay showed that 5-FU significantly
inhibited HUVEC growth; while IFN-α had mild short-
term growth inhibitory effects even when used at a high
dose. To evaluate the long-term effects of IFN-α or the syn-
ergistic anti-proliferative effects of IFN-α and 5-FU on
endothelial cells, we performed cell growth assay by cell
counts methods. At 500 IU/ml, IFN-α alone significantly
inhibited HUVEC growth on 7th day, compared to the
control.
Furthermore, the combination of IFN-α and 5-FU signifi-
cantly inhibited the growth of HUVEC on 5th and 7th
day, compared to the control, 5-FU or IFN-α alone. IFNs
have multiple biological actions causing modulation of
gene expression, immunomodulation and regulation of
cell cycle. IFNs also inhibit endothelial cell growth in vitro.
Our results are consistent with those of previous reports,
which showed that IFNs has anti-proliferative properties
on endothelial cells [31,32]. Moreover, the combination
of IFN-α and 5-FU synergistically inhibited HUVEC
growth. In this regard, Solorzano et al. [18] reported that
the combination with IFN and gemcitabine synergistically
induced endothelial cell apoptosis using in vivo orthotop-
ical pancreas cancer models.
Is the growth inhibitory effect of IFN/5-FU due to induc-
tion of apoptosis, cell cycle arrest or inhibition of DNA
synthesis? To answer this question, we used the BrdUrd
labeling assay and showed that 5-FU significantly inhib-
ited DNA synthesis 24 hours after the administration;
although there was no apparent difference in the BrdUrd
labeling index between control and IFN-α alone. TUNEL
assay and Annexin-V assay showed that none of the agents
used induced apoptosis of endothelial cells. These results
are in agreement with those of Hong et al [31] who
reported that IFN-α significantly inhibited HUVEC
growth but did not induce apoptosis of IFN-α treated
HUVC. We also reported previously that IFN/5-FU did not
(A) Knock-down of Ang-1 or Ang-2 efficiently represses the expression of Ang-1 or Ang-2 mRNA in HuH-7 cells Figure 6
(A) Knock-down of Ang-1 or Ang-2 efficiently represses the expression of Ang-1 or Ang-2 mRNA in HuH-7 
cells. HuH-7 cells were transfected to Ang-1 or Ang-2 siRNA. Forty eight hours after the transfection, we evaluated the 
expression of Ang-1 or Ang-2 mRNA by real time RT-PCR. Values shown are relative induction of the indicated genes. (B) The 
supernatant of HuH-7 cells after knockdown of Ang-1 completely abrogated the anti-proliferative effects of the conditioned 
medium from IFN/5-FU treated HuH-7 cells. HuH-7 cells treated with siRNA for Ang-1, Ang-2 or non-specific for 24 hours, 
and then we collected the supernatant after treatment with or without IFN/5-FU for 48 hours. We evaluated viability of 
HUVEC cells by MTT assay. The percentage of viable cells was significantly reduced by the conditioned media after the treat-
ment of IFN/5-FU. There is no significant difference between the conditioned media after treatment with or without IFN/5-FU 
after knockdown of Ang-1 or Ang-2.BMC Cancer 2009, 9:361 http://www.biomedcentral.com/1471-2407/9/361
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induce apoptosis of cultured normal liver epithelial cells
in vitro or hepatocytes in patients who underwent hepate-
ctomy after IFN/5-FU combination therapy, although the
combination treatment induced apoptosis of tumor cells
[14] These results suggest that non-cancerous cells are
resistant to apoptosis induced by IFN/5-FU. Analysis of
cell cycle progression in HUVEC provided a clue to the
anti-proliferative mechanism of IFN/5-FU on endothelial
cells. A marked delay in cell cycle progression was found
in IFN/5-FU-treated cells with S-phase accumulation. In
cells treated with IFN-α only, a slight accumulation of
cells at the S-phase was also detected. The link between
cell cycle regulation and IFN has been reported previ-
ously. IFN-α is reported to induce G1 phase arrest in
murine fibroblasts (NIH-3T3), human Burkitt's lym-
phoma cell line (Daudi) and the lymphoid cell line U-266
[33-35]. We also reported that IFN/5-FU induced a
marked accumulation of G0-G1 phase by regulating
p27kip1 expression in IFN-sensitive human HCC cell line,
PLC/PRF/5 [12]. IFN has additional effects on the cell
cycle, including S phase prolongation, S phase block and
G2/M arrest. Yano et al. [36] investigated the anti-prolifer-
ative effects of IFN in 13 human HCC cell lines and
reported blockade of cell cycle at S-phase in 11 of 13 cell
lines. We also examined the effects of IFN or 5-FU on tube
formation. Several investigators reported that IFN inhib-
ited endothelial cell tube formation both in vitro and in
vivo  [31,32]. Our results confirmed that IFN-α signifi-
cantly inhibited HUVEC-tube formation in vitro, consist-
ent with the previous reports; no additional effect for 5-FU
was noted on endothelial cell tube formation.
Does the combination of IFN/5-FU have an indirect anti-
angiogenic effect on tumor cells? To answer this question,
we examined the concentrations and effects of angiogenic
factors released from human HCC cell line, HuH7, in the
presence and of absence of IFN and 5-FU and their com-
bination. This approach was based on the fact that angio-
genesis is also known to be caused by host and tumor cells
reactions. Supernatants from HuH-7 treated with IFN/5-
FU significantly inhibited HUVEC growth and induced
apoptosis. ELISA assays showed significant reduction of
VEGF and Ang-2 and increased Ang-1 in supernatant of
IFN/5-FU-treated HUVEC. VEGF and angiopoietins play
crucial roles in cancer angiogenesis in various malignan-
cies including HCC. VEGF was initially identified as a vas-
cular permeability factor and is known to evoke
proliferation and migration of endothelial cells, and to
inhibit apoptosis in pathological angiogenesis [37-39].
VEGF and its receptors are upregulated in various cancers
[40] and overexpression of VEGF correlates with micro-
vessel density (MVD), invasiveness and poor prognosis
[41]. Angiopoietins are members of endothelial growth
factors and have been identified as secreted ligands for
receptor-like tyrosine kinase Tie2 [42-44]. Four members
of angiopoietins have been detected in recent studies.
Ang-1 induces phosphorylation of Tie2 as an agonist and
acts as a survival factor for endothelial cells to promote
recruitment of pericytes and smooth muscle cells. Ang-2
can also bind with Tie2 but does not induce its phospho-
rylation. Ang-2 is a biological antagonist and reduces vas-
cular stability. VEGF and angiopoietins play
complementary and coordinated roles in vascular devel-
opment. In the presence of VEGF, Ang-2 promotes vascu-
lar sprouting and angiogenesis [45]. High expression of
Ang-2 is detected in highly vascular remodeling organs
such as the ovaries and placenta. Several investigators
reported that the high expression of Ang-2 correlated with
MVD or clinicopathological factors in several malignan-
cies including HCC [46-50]. We reported previously that
the expression of VEGF and Ang-2 protein correlated with
hypervascularity, differentiation and poor prognosis of
HCC [50]. Our recent study also showed that IFN/5-FU
significantly inhibited in vivo angiogenesis of HCC cells
with regulation of the VEGF, Ang-1 and Ang-2 expression
[16].
To evaluate whether angiopoietins affected by IFN/5-FU
play an important role in growth inhibition and apoptosis
of HUVEC, we performed rescue experiments with siRNAs
knockdown of Ang-1 or Ang-2. Knockdown of Ang-1
abrogated the anti-proliferative effects of the conditioned
medium from IFN/5-FU-treated HUVEC while that of
Ang-2 resulted in partial rescue. These results suggest that
IFN and 5-FU when used in combination regulate the
expression of angiopoietins and that these proteins con-
tribute, at least in part, to the anti-angiogenic effects of
IFN/5-FU. Further studies are needed to define the exact
regulatory mechanisms of angiopoietins by IFN-α and 5-
FU and the transcriptional regulation of angiopoietins.
IFN-α exerts most of its biological activity by altering the
level of gene expression in target cells [51]. Tumor-derived
VEGF up-regulates the expression of Ang-2 in host stromal
endothelial cells [52]. Battle et al. [53] reported that signal
transducer and activator of transcription (STAT) 1, which
is one of the signal transducers of IFN, was a negative reg-
ulator of angiogenesis and that IFN inhibited Ang-2
expression induced by VEGF. Dickson et al. [54] reported
recently that IFN directly up-regulated the expression of
Ang-1 on tumor cells in vitro. It influenced IFN-mediated
remodeling of intra-tumoral vasculature and improved
drug delivery in vivo. These results suggest that regulation
of angiopoietins by IFN causes vascular stabilization,
reduces vessel permeability and enhances the anti-tumor
effects of 5-FU by improvement of drug delivery to
tumors.
Conclusion
We confirmed that the combination of IFN-α and 5-FU
had direct anti-proliferative effects on HUVEC and thatBMC Cancer 2009, 9:361 http://www.biomedcentral.com/1471-2407/9/361
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their synergistic effects were mediated through delays of
cell cycle in HUVEC. IFN-α and 5-FU also regulated the
expression of VEGF, Ang1 and Ang2 secreted by tumor
cells. These actions seem to explain, at least in part, the in
vitro anti-angiogenic effects of IFN/5-FU, suggesting that
they could also contribute to the synergistic anti-tumor
effects of these compounds on HCC through remodeling
of tumor vasculature and modulating drug delivery.
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